About Ori Biotech
Ori Biotech develops a proprietary, flexible manufacturing platform. It closes, automates, and standardizes manufacturing, allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The company was founded in 2015 and is based in London, United Kingdom.
Ori Biotech's Products & Differentiators
We are in the pre-launch phase
Expert Collections containing Ori Biotech
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Ori Biotech is included in 2 Expert Collections, including Robotics.
This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.
Companies in the advanced manufacturing tech space, including companies focusing on technologies across R&D, mass production, or sustainability
Ori Biotech Patents
Ori Biotech has filed 16 patents.
Fluid dynamics, Biotechnology, Cell biology, Medical equipment, Stem cells
Fluid dynamics, Biotechnology, Cell biology, Medical equipment, Stem cells
Latest Ori Biotech News
Nov 17, 2023
Ori Biotech LEAPs forward toward commercialization in 2024 Search jobs Ori Biotech LEAPs forward toward commercialization in 2024 London, UK, November 15th, 2023 – Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces new additions to the executive team to support the commercial launch of its platform and the status of enrollment into their oversubscribed Lightspeed Early Access Program (LEAP). Ori has appointed Gillian Bonthron as Chief Financial Officer and John Machulski as Chief Operating Officer. Gillian joins Ori with a wealth of expertise in transactional finance, financial strategy and leadership within health technology, most recently at Healx and Perspectum. She has worked globally in senior finance and consulting roles. John, joins from Catalent, bringing extensive operational experience to Ori from past leadership roles at Lonza, GE Life Sciences (now Cytiva), Sanofi, Pfizer and J&J. John’s roles have covered operations, engineering and commercial, and included the building and startup of multiple cell and gene therapy manufacturing facilities in the US, Europe, and Asia. In addition to these new senior additions, Thomas Heathman, Ph.D has been promoted to Chief Commercial Officer and will lead the upcoming commercial launch of Ori’s cell therapy manufacturing platform. Ori has also added additional expertise to its already world-class Advisory Board to support as the company enters the commercial phase. The following industry experts have recently been added to the Strategic Advisory Board: Jim Faulkner PhD, CTO at Ascidian Therapeutics and former SVP, Product Delivery at Autolus Matthew Hewitt PhD , Vice President, Technical Officer CGT & Biologics at Charles River Maik Jornitz , Former CEO G-Con, Board Member Sunflower Therapeutics, DIANT Pharma Bruce Thompson PhD, CEO at Kincell Bio Ori’s full-stack manufacturing system fully automates, digitizes and standardizes CGT manufacturing, enabling therapy developers to seamlessly transition from pre-clinical process discovery to commercial scale. The platform’s hardware, software and analytical tools promise increased throughput and reproducibility, while reducing costs – ultimately helping manufacture life-saving therapies at scale, in order to enable widespread patient access. Bruce Thompson PhD stated, “As the CGT industry continues to mature, we need technologies that are flexible enough for use in R&D and process development as well as scalable enough to enable commercial manufacturing. The Ori platform has incredible potential to shorten development times, lower COGS, increase throughput and improve consistency. We are pleased to join the Ori Biotech Strategic Advisory Board and excited to advise the company as they make this revolutionary technology commercially available.” Taking a LEAP toward commercialization Since 2022, Ori’s LEAP program has been giving leading industry partners, like Inceptor Bio , CTMC (a joint venture between Resilience and MD Anderson ), adthera bio and an undisclosed big pharma partner, access to Ori’s proprietary CGT manufacturing platform prior to commercial launch in 2024. These LEAP partners have been doing feasibility testing of Ori’s digitally native manufacturing platform to accelerate their progress toward the scalable production of novel cell therapies. Ori’s CCO Thomas Heathman remarked: “We are looking forward to seeing our first product reach the market so we can begin enabling our partners to deliver cell therapies to more patients in need. Our team, our advisors and our partners have the deep expertise necessary to ensure our platform delivers on both the research and GMP requirements for flexible and scalable manufacturing that our industry requires. Our collective ambition is to ensure that this new generation of therapies are not just approvable, but also affordable and accessible.” Jason C Foster, CEO of Ori Biotech added: “If we can’t produce cell and gene therapies affordably, and at scale, their potential may never be realized. Over the last 3 years, we have generated best-in-class biological data from over 500 runs, with 9 different partners, using 10 different protocols to demonstrate the potential of the Ori platform. We are honored to be joined by experienced industry veterans and key opinion leaders on our mission to enable widespread patient access to life-saving cell and gene therapies.” View the Ori platform scientific results presented at the Alliance for Regenerative Medicine’s Meeting on the Mesa. About Ori Biotech Ori is a London and New Jersey-based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and gene therapies. Ori has developed a proprietary, full-stack manufacturing platform that closes, automates and standardizes CGT manufacturing, allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the innovative Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining proprietary hardware, software, data and analytics. For more information, visit oribiotech.com. Editor Details
Ori Biotech Frequently Asked Questions (FAQ)
When was Ori Biotech founded?
Ori Biotech was founded in 2015.
Where is Ori Biotech's headquarters?
Ori Biotech's headquarters is located at London Biosciences Innovation Centre, London.
What is Ori Biotech's latest funding round?
Ori Biotech's latest funding round is Series B.
How much did Ori Biotech raise?
Ori Biotech raised a total of $139.4M.
Who are the investors of Ori Biotech?
Investors of Ori Biotech include Amadeus Capital Partners, Delin Ventures, Octopus Ventures, Northpond Ventures, Novalis LifeSciences and 5 more.
Who are Ori Biotech's competitors?
Competitors of Ori Biotech include Cellares and 2 more.
What products does Ori Biotech offer?
Ori Biotech's products include TBD.
Compare Ori Biotech to Competitors
Cellares provides a cell therapy manufacturing technology platform. It focuses on Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing. It was founded in 2019 and is based in South San Francisco, California.
Multiply Labs builds robotic devices to produce customized medications. It manufactures cloud-controlled robotic systems enabling the production of individualized drugs at scale. Multiply Labs was formerly known as Pharmacube. The company was founded in 2016 and is based in San Fransico, California.
Cellino develops an intracellular delivery technique for gene editing applications. The company provides stem cell-derived regenerative medicines that are poised to cure tough diseases, including Parkinson’s, diabetes, and heart disease. It combines label-free imaging and laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format. It was founded in 2017 and is based in Cambridge, Massachusetts.
OneFul personalizes multi-drug chronic therapies formulated using digital health data, combining 3-7 prescriptions of individually dosed high-potency drugs. It seeks to improve the quality of life for millions of patients with affordable personalized medicine that are much easier to take. It delivers multiple drugs combined for a person, as prescribed by the doctor from its modern OneFul Pharmacies by using precision medicine science and made with robotic accuracy. It was founded in 2013 and is based in Durham, North Carolina.
Equashield provides automated solutions to protect healthcare workers and facilities from the risks associated with hazardous drug exposure and contamination. The company offers closed-back syringes and automated compounding robots to optimize the daily ability to safety. It was founded in 2009 and is based in Port Washington, New York.
Panaceutics Nutrition focuses on the health and wellness industry, specifically in the domain of personalized nutrition. The company's main service is the creation of personalized nutritional supplements, tailored to the unique health profiles of individuals, eliminating the need for traditional pills and powders. Its primary market is individuals seeking to optimize their health and wellness through personalized supplementation. It was formerly known as Panacea BioMatx. It was founded in 2013 and is based in Richmond, Virginia.